Free Trial

Nabriva Therapeutics (NBRV) News Today

→ Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad)
Free NBRV Stock Alerts
Compare
Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends
June 5, 2024 | americanbankingnews.com
Nabriva Therapeutics (NASDAQ:NBRV) Receives New Coverage from Analysts at StockNews.com
April 13, 2024 | morningstar.com
Nabriva Therapeutics PLC NBRVF
July 11, 2023 | finanznachrichten.de
Arbutus Biopharma Corporation: Arbutus Appoints Two New Executives
May 26, 2023 | finance.yahoo.com
NBRV - Nabriva Therapeutics plc
March 27, 2023 | marketbeat.com
Trading was temporarily halted for "NBRV" at 09:03 AM with a stated reason of "LULD pause."
February 28, 2023 | marketwatch.com
Bacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029
February 25, 2023 | seekingalpha.com
NBRV Nabriva Therapeutics plc
January 6, 2023 | finance.yahoo.com
Nabriva Therapeutics Provides Corporate Update
November 28, 2022 | marketwatch.com
Nabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial Data
November 28, 2022 | markets.businessinsider.com
Nabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic Fibrosis
November 28, 2022 | markets.businessinsider.com
Nabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock Up
November 28, 2022 | bizjournals.com
Nabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatment
November 28, 2022 | seekingalpha.com
Nabriva gains after announcing Phase 1 data for cystic fibrosis candidate
November 28, 2022 | finance.yahoo.com
Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
November 28, 2022 | finance.yahoo.com
Nabriva's stock is up after sharing antibiotic news
November 28, 2022 | finance.yahoo.com
Nabriva's antibiotic shows promise as a potential cystic fibrosis treatment
November 10, 2022 | finance.yahoo.com
Montgomery County biopharmaceutical firm reducing workforce by 40%
November 10, 2022 | technews.tmcnet.com
Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
November 10, 2022 | finance.yahoo.com
Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
November 7, 2022 | finance.yahoo.com
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
September 18, 2022 | marketbeat.com
Nabriva Therapeutics plc (NASDAQ:NBRV) Sees Significant Drop in Short Interest
Nabriva Therapeutics plc (NASDAQ:NBRV - Get Rating) was the recipient of a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 532,200 shares, a drop of 13.0% from the August 15th total of 611,800 shares. Based on an average trading volume of 804,800 shares, the short-interest ratio is presently 0.7 days.
September 16, 2022 | marketbeat.com
Nabriva Therapeutics (NASDAQ:NBRV) Reaches New 12-Month High on Analyst Upgrade
Nabriva Therapeutics (NASDAQ:NBRV) Reaches New 12-Month High on Analyst Upgrade
September 15, 2022 | finance.yahoo.com
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
September 14, 2022 | finance.yahoo.com
All You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buy
September 6, 2022 | finance.yahoo.com
Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 15, 2022 | marketbeat.com
Nabriva Therapeutics plc (NASDAQ:NBRV) Short Interest Up 24.1% in July
Nabriva Therapeutics plc (NASDAQ:NBRV - Get Rating) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 709,000 shares, an increase of 24.1% from the July 15th total of 571,100 shares. Based on an average trading volume of 807,800 shares, the days-to-cover ratio is currently 0.9 days.
August 12, 2022 | marketwatch.com
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic Fibrosis
August 11, 2022 | finance.yahoo.com
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
August 4, 2022 | seekingalpha.com
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2022 Results - Earnings Call Transcript
August 3, 2022 | finance.yahoo.com
Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
July 27, 2022 | marketbeat.com
Nabriva Therapeutics (NBRV) to Release Quarterly Earnings on Wednesday
Nabriva Therapeutics (NASDAQ:NBRV) will be releasing earnings after the market closes on Wednesday, August 3, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=465996)
July 20, 2022 | finance.yahoo.com
Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022
July 18, 2022 | markets.businessinsider.com
Nabriva Inks Exclusive Distribution Agreement With Er-Kim
July 18, 2022 | finance.yahoo.com
Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals
May 31, 2022 | marketbeat.com
Nabriva Therapeutics plc (NASDAQ:NBRV) Sees Large Decline in Short Interest
Nabriva Therapeutics plc (NASDAQ:NBRV - Get Rating) was the target of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 535,500 shares, a decrease of 21.0% from the April 30th total of 677,700 shares. Based on an average trading volume of 475,200 shares, the short-interest ratio is currently 1.1 days.
May 25, 2022 | marketbeat.com
$9.47 Million in Sales Expected for Nabriva Therapeutics plc (NASDAQ:NBRV) This Quarter
Brokerages predict that Nabriva Therapeutics plc (NASDAQ:NBRV - Get Rating) will report $9.47 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Nabriva Therapeutics' earnings. The highest sales estimate is $10.40 million and the lowest is $8.
May 13, 2022 | finance.yahoo.com
Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 8, 2022 | seekingalpha.com
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2022 Results - Earnings Call Transcript
May 5, 2022 | finance.yahoo.com
Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 5, 2022 | seekingalpha.com
Nabriva extends exclusive contract to sell Merck's antibacterial drug Sivextro in US
May 5, 2022 | finance.yahoo.com
Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026
May 4, 2022 | benzinga.com
A Preview Of Nabriva Therapeutics's Earnings
May 2, 2022 | finance.yahoo.com
Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022
April 11, 2022 | finance.yahoo.com
Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
March 30, 2022 | seekingalpha.com
Northland Securities slashes Nabriva Therapeutics' price target
March 30, 2022 | marketbeat.com
Nabriva Therapeutics (NASDAQ:NBRV) Price Target Cut to $2.00
Northland Securities dropped their price objective on Nabriva Therapeutics from $4.00 to $2.00 in a research note on Wednesday.
March 29, 2022 | seekingalpha.com
Nabriva Therapeutics plc 2021 Q4 - Results - Earnings Call Presentation
March 29, 2022 | investing.com
Nabriva Therapeutics Earnings, Revenue Miss in Q1
March 29, 2022 | seekingalpha.com
Nabriva 4Q results indicate slowdown in topline growth
March 29, 2022 | finance.yahoo.com
Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
Get Nabriva Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.

Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)

In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.

You just have to make this simple move before July 30, 2024.

NBRV Media Mentions By Week

NBRV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NBRV
News Sentiment
▼
0.00

0.76
▲
Average
Medical
News Sentiment

NBRV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NBRV Articles
This Week
▼
1

0
▲
NBRV Articles
Average Week

Get Nabriva Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:NBRV) was last updated on 6/9/2024 by MarketBeat.com Staff

From Our Partners
Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...
Colonial Metals | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on...
Paradigm Press | Sponsored
Urgent alert: open this for a huge profit potential
This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...
Timothy Sykes | Sponsored
Are You Positioned For The New Energy Goldrush?
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored